Evidence map›Paper›PMID 42845845›Full record

Trial reportOpen forum infectious diseases2026

A Systematic Review and Network Meta-analysis of Empirical Antibiotics for Complicated Urinary Tract Infections.

Lior Cohen-Yatziv, Emily Gilbert, Ruiwen Zhou, Maria Cristina Vazquez Guillamet

Abstract readClinical Trial
In one paragraph

Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lior Cohen-YatzivDivision of Infectious Diseases, Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-0496-4726
Emily GilbertLibrary of the Health Sciences, University of Illinois Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-9928-2105
Ruiwen ZhouCenter for Biostatistics and Data Science, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0001-6258-2091
Maria Cristina Vazquez GuillametDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0003-4280-9804

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Empiric antibiotic selection for complicated urinary tract infections (cUTIs) is increasingly complex due to the rising prevalence of multidrug-resistant organisms. We conducted a network meta-analysis (NMA) to compare clinical efficacy and safety among existing empiric treatment options. Methods: We performed a frequentist random-effects NMA of randomized controlled trials evaluating single-agent empiric regimens for adults with cUTIs. The primary endpoints were clinical response (CR), microbiological response, and serious adverse events (AEs). Ceftriaxone served as the common comparator. Results: Forty-seven trials were identified through a systematic search. In the primary analysis of 17 studies published after the year 2000, evaluating agents currently accessible in the United States, in which baseline ceftriaxone non-susceptibility among Enterobacterales averaged approximately 15%. Ceftriaxone demonstrated CR rates comparable to broader-spectrum alternatives. Although some agents achieved higher microbiological eradication, these differences did not translate into superior clinical cure rates. Safety profiles were stable across antibiotic classes, with no significant differences in serious AEs compared to cephalosporins. Conclusions: Ceftriaxone remains an effective empiric option for hemodynamically stable adults with cUTIs in settings with comparable resistance prevalence. These findings provide evidence to support antimicrobial stewardship efforts that prioritize narrower-spectrum agents, preserving broader-spectrum therapies for patients at highest risk for resistant pathogens.

Indexed as

antimicrobial stewardshipbeta-lactam antibioticscomplicated urinary tract infectionsnetwork meta-analysisrandomized controlled trials

Identifiers

PMID42845845
PMCPMC13642042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.